Cargando…

Current position of 5HT(3) antagonists and the additional value of NK(1) antagonists; a new class of antiemetics

The advent of the 5HT(3) receptor antagonists (5HT(3) antagonists) in the 1990 s and the combination with dexamethasone has resulted in acute emesis protection in 70% of patients receiving highly emetogenic chemotherapy. Despite complete protection in the acute phase, however, 40% of patients as yet...

Descripción completa

Detalles Bibliográficos
Autor principal: de Wit, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741127/
https://www.ncbi.nlm.nih.gov/pubmed/12799621
http://dx.doi.org/10.1038/sj.bjc.6601033

Ejemplares similares